Key result
Treatment of T-lymphoblastic leukemia cells with anthracyclines altered 1%-2% of detected proteins, primarily those involved in metabolic and cellular processes.
Why the study?
Does treatment with anthracyclines/anthracenediones alter the proteome of T-lymphoblastic leukemia cells?
Does treatment with anthracyclines/anthracenediones alter the proteome of T-lymphoblastic leukemia cells?
Proteomic profiling reveals distinct early protein alterations in T-lymphoblastic leukemia cells treated with different anthracyclines, highlighting specific pathways that may explain their anti-cancer activity.
Hypothesis-generating for anthracycline mechanisms in T-ALL; prospective validation required before any clinical consideration.
A comprehensive proteome map of T-lymphoblastic leukemia cells and its alterations after daunorubicin, doxorubicin and mitoxantrone treatments was monitored and evaluated either by paired comparison with relevant untreated control and using multivariate classification of treated and untreated samples. With the main focus on early time intervals when the influence of apoptosis is minimized, we found significantly different levels of proteins, which corresponded to 1%-2% of the total amount of protein spots detected. According to Gene Ontology classification of biological processes, the highest representation of identified proteins for all three drugs belong to metabolic processes of proteins and nucleic acids and cellular processes, mainly cytoskeleton organisation and ubiquitin-proteasome pathway. Importantly, we observed significant proportion of changes in proteins involved in the generation of precursor metabolites and energy typical for daunorubicin, transport proteins participating in response to doxorubicin and a group of proteins of immune system characterising response to mitoxantrone. Both a paired comparison and the multivariate evaluation of quantitative data revealed daunorubicin as a distinct member of the group of anthracycline/anthracenedione drugs. A combination of identified drug specific protein changes, which may help to explain anti-cancer activity, together with the benefit of blocking activation of adaptive cancer pathways, presents important approaches to improving treatment outcomes in cancer.
No takes yet. Share an insight, caveat, or question.
Tylečková et al. (2012) studied T-lymphoblastic leukemia. Daunorubicin, doxorubicin, and mitoxantrone vs. Untreated control was evaluated on Proteome map alterations. Treatment of T-lymphoblastic leukemia cells with anthracyclines altered 1%-2% of detected proteins, primarily those involved in metabolic and cellular processes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: